Last reviewed · How we verify
HRS9531 Tablet — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
HRS9531 Tablet (HRS9531 Tablet) — Fujian Shengdi Pharmaceutical Co., Ltd.. HRS9531 Tablet's mechanism of action is not publicly available.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HRS9531 Tablet TARGET | HRS9531 Tablet | Fujian Shengdi Pharmaceutical Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HRS9531 Tablet CI watch — RSS
- HRS9531 Tablet CI watch — Atom
- HRS9531 Tablet CI watch — JSON
- HRS9531 Tablet alone — RSS
Cite this brief
Drug Landscape (2026). HRS9531 Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs9531-tablet. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab